Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.

Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.

Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.